US 9,808,553 B2
Haemostatic wound dressing
Greg Walker, Dunedin (NZ); and Sarah Margaret Middleton, Nottingham (GB)
Assigned to HAEMOSTATIX LIMITED, Nottingham, Nottinghamshire (GB)
Appl. No. 14/376,023
Filed by Haemostatix Limited, Nottingham, Nottinghamshire (GB)
PCT Filed Feb. 1, 2013, PCT No. PCT/GB2013/050237
§ 371(c)(1), (2) Date Jul. 31, 2014,
PCT Pub. No. WO2013/114132, PCT Pub. Date Aug. 8, 2013.
Claims priority of application No. 1201751.3 (GB), filed on Feb. 1, 2012.
Prior Publication US 2015/0071985 A1, Mar. 12, 2015
Int. Cl. A61K 38/00 (2006.01); C07K 9/00 (2006.01); A61L 24/00 (2006.01); A61L 15/32 (2006.01); A61L 15/42 (2006.01); A61L 15/44 (2006.01); A61L 24/10 (2006.01)
CPC A61L 24/0015 (2013.01) [A61L 15/325 (2013.01); A61L 15/425 (2013.01); A61L 15/44 (2013.01); A61L 24/0036 (2013.01); A61L 24/0073 (2013.01); A61L 24/108 (2013.01); A61L 2300/25 (2013.01); A61L 2300/252 (2013.01); A61L 2300/418 (2013.01); A61L 2300/606 (2013.01); A61L 2400/04 (2013.01); A61L 2400/18 (2013.01)] 25 Claims
 
1. A haemostatic wound dressing, which comprises a non-colloidal porous dressing material, and a plurality of fibrinogen-binding peptides immobilized to the non-colloidal porous dressing material, wherein each fibrinogen-binding peptide comprises:
an amino acid sequence Gly-Pro-Arg-Xaa (SEQ ID NO: 1) at an amino-terminal end of the peptide, wherein Xaa is any amino acid other than Val; or
an amino acid sequence Gly-His-Arg-Xaa (SEQ ID NO: 2) at an amino-terminal end of the peptide, wherein Xaa is any amino acid other than Pro,
wherein the non-colloidal porous dressing material comprises a sheet, pad, sponge, foam, film, gauze, mesh, granules or beads, wherein if the non-collodial porous dressing material comprises granules or beads, a majority of the granules or beads have a maximum dimension that is greater than 6 μm, and
wherein a plurality of carriers are immobilized to the non-colloidal porous dressing material, and the plurality fibrinogen binding peptides are covalently immobilized to each carrier.